Annual Report 2006 - Boehringer Ingelheim

More documents

Recommendations

Info

cal exercise capacity and the reduction of exacerbations in COPD. spiriva® is now the first COPD drug which incorporates information about exacerbations and exercise in a broad population of COPD patients on its label. spiriva® is currently delivered to patients via our HandiHaler® device. In future, patients will also be able to benefit from spiriva® delivered via Boehringer Ingelheim’s respimat® Soft Mist Inhaler (SMI), a novel propellant-free, multi-dose, inhaler that generates a slow-moving, long-lasting cloud (the soft mist) with a high fine particle fraction (less than 5.8 μm). As a result, deposition “I feel now like another man” “I have smoked for 30 years which has left me with chronic obstructive pulmonary disease,” says seventy-year-old Frenchman Jacques Luchier, a retired food industry bacteriologist. “The first time I met my pulmonary specialist and he told me I had very severe COPD, I was caught completely off guard. I was scared, as you think about death and that you’ll end up in a hospital bed with tubes everywhere to keep you alive.” COPD causes significant deterioration of lung function resulting in breathlessness, activity limitation and associated disability. Some 600 million people currently live with COPD, and the disease is projected to be the world’s third leading cause of death by 2020. serving patients Jacques Luchier started treatment with a novel bronchodilator. He also undertakes respiratory rehabilitation which consists of regular supervised exercise, education on COPD and its treatment, breathing techniques, as well as nutritional and psychological support. “The respiratory rehabilitation is very hard to cope with at the start. You have to really make an effort,” Jacques says. “But you get to improve your quality of life by inhaling the bronchodilator. You feel relief, you breathe better, you feel more yourself, you recover your spirits”. And he adds: “Now I feel like another man. I feel distinctly better. I feel less handicapped.” of the drug in the lungs is improved and less deposition occurs in the mouth and throat compared to pressurised metered dose inhalers. Attitudes of patients show a high level of satisfaction with this device. After completion of the pivotal studies for spiriva® in our propellant-free respimat® SMI we have submitted a registration file in the EU under the “decentralised procedure” and in addition in several other countries around the world. The completion of the US submission will be one of our key activities for 2007. Prescription Medicines 1
Our R & D for respiratory diseases Our worldwide launch of spiriva® (tiotropium) provided a medication to improve COPD therapy and strengthened our leading position in this field. We are striving for further innovations by devel- oping bronchodilators with alternative mechanisms. These new bronchodilators are being for- mulated in innovative inhalation devices. In addition, Boehringer Ingelheim in 2006 entered into a worldwide collaboration, development and licence agreement with the British company Vectura. The aim of the collaboration is to develop a multi-dose dry powder inhaler as a Boehringer Ingelheim branded device, to deliver a range of proprietary Boehringer Ingelheim respiratory products, mainly for the treatment of COPD and asthma. We currently have numerous bronchodilator programmes in development, six of them in clinical studies. Extending our product portfolio to drugs that target treatment of the underlying inflammation and the tissue remodelling process are further key goals in our COPD research. Inflammation in COPD patients is provoked by an infiltration of the lungs by macrophages and neutrophils. This is only poorly controlled by current, widelyused anti-inflammatory drugs, such as corticosteroids. We are therefore working on alternative anti-inflammatory mechanisms, specifically targeting macrophage and neutrophil-driven inflammation. In addition, we aim at preventing or delaying tissue remodelling that is induced by chronic inflammation by targeting lung growth factors. Two first-in-class mechanisms targeting mucous hyperplasia and fibrosis are being tested clinically. Beyond COPD, such new mechanisms have a therapeutic potential in idiopathic pulmonary fibrosis (IPF), a life-threatening disease, and in Boehringer Ingelheim A n n u A l R e p o R t 2 0 0 6 severe asthma, where mucous plugging is considered the main cause of death. Our research in asthma is aimed at new mechanisms and immunological paradigms that would allow us to replace or reduce the doses of inhaled steroids by providing anti-inflammatory therapy better tolerated by patients. Another goal is to provide a new treatment for specific syndromes with high, unmet medical need, such as severe, steroid-resistant asthma. Diseases of the central nervous system According to World Health Organization (WHO) predictions, diseases of the central nervous system will constitute an increasing medical need in this century, attributable to an exponential increase of these diseases in patients beyond 65 years of age, combined with an aging population. To date, available therapeutic treatments are still unsatisfactory for the majority of CNS diseases.
Page 1 and 2:
Value through Innovation Annual Rep
Page 3 and 4: Contents 1 Value Through Innovation
Page 5 and 6: The Shareholders’ Perspective Dea
Page 7 and 8: Key Aspects of 2006 2006 was again
Page 9 and 10: This growth was clearly restrained
Page 11 and 12: Shareholders’ Committee Dr Heribe
Page 13 and 14: “There is help” “The woman wh
Page 15 and 16: 1 continued from page 10 A Kenyan m
Page 17 and 18: 1 Our people In pursuing our vision
Page 19 and 20: Company childcare enters new territ
Page 21 and 22: 1 Caring for our neighbours We are
Page 23 and 24: 0 Children from St Margaret Clither
Page 25 and 26: Our environment & employee safety A
Page 27 and 28: thanks to the use of the wood-fired
Page 29 and 30: Our goals We shall continue to inve
Page 31 and 32: Targeting tomorrow’s therapies Th
Page 33 and 34: 0 continued from page 28 “Boehrin
Page 35 and 36: Our R & D strategy Research and dev
Page 37 and 38: Ridgefield, USA Cardiovascular, imm
Page 39 and 40: Vienna, Austria Oncology Boehringer
Page 41 and 42: Our expertise in landmark studies L
Page 43 and 44: From mind to man - the R & D proces
Page 45 and 46: New biological entities (NBE) One o
Page 47 and 48: The development of our businesses W
Page 49: Rin Fujima, Kyoto, Japan, suffers f
Page 52 and 53: Human Pharmaceuticals Branded presc
Page 56 and 57: “Like a great round of golf“
Page 58 and 59: gives patients a better chance of g
Page 60 and 61: aptivus® was launched in the USA i
Page 62 and 63: enzymes, such as the HCV serine pro
Page 64 and 65: Børge Madsen, Copenhagen, Denmark.
Page 66 and 67: Cardiovascular diseases Despite sig
Page 68 and 69: actilyse® is the first and only th
Page 70 and 71: fibrillation in some 40 countries i
Page 72 and 73: Treatment modalities used to reliev
Page 74 and 75: HuCAL antibody directed against a c
Page 76 and 77: hand, the end of exclusivity in Eur
Page 78 and 79: Generic Prescription Medicines The
Page 80 and 81: Ben Venue - a world leader in steri
Page 82 and 83: Mara Lovera, Buenos Aires, Argentin
Page 84 and 85: Consumer Health Care Our Consumer H
Page 86 and 87: Switching reinforces the trend towa
Page 88 and 89: Alexander (left) and Christopher pl
Page 90 and 91: Animal Health The sound progress of
Page 92 and 93: located, trained and placed with fi
Page 94 and 95: Our Customer Orientation Our custom
Page 96 and 97: On a biopharmaceutical compound’s
Page 98 and 99: Pharmaceuticals Production Our Phar
Page 100 and 101: Counterfeits - a real threat for pa
Page 102 and 103: Group Management Report 2006
Page 104 and 105:
companies lost their patent protect
Page 106 and 107:
To summarise, we see the success of
Page 108 and 109:
Production Production sites belongi
Page 110 and 111:
In the area of HIV/AIDS therapy, we
Page 112 and 113:
only 2 %. The region’s overall ne
Page 114 and 115:
of the cash flow, which rose by EUR
Page 116 and 117:
Report on expected developments The
Page 118 and 119:
Consolidated Financial Statements 2
Page 120 and 121:
C. H. Boehringer Sohn Grundstücksv
Page 122 and 123:
C. H. Boehringer Sohn, Ingelheim Co
Page 124 and 125:
C. H. Boehringer Sohn, Ingelheim St
Page 126 and 127:
The following subsidiaries were exe
Page 128 and 129:
2 Accounting and evaluation methods
Page 130 and 131:
3 Notes to the consolidated balance
Page 132 and 133:
3.3 Financial assets (in millions o
Page 134 and 135:
Pension provisions Boehringer Ingel
Page 136 and 137:
4 Notes to the consolidated profit
Page 138 and 139:
4.7 Holding income (in millions of
Page 140 and 141:
Other mandatory disclosures accordi
Page 142 and 143:
Derivative financial instruments at
Page 144 and 145:
With the following exception, our a
Page 146 and 147:
Product name Active ingredient Indi
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Comparison of Balance Sheets/ Finan
show all

Annual Report 2006 - Boehringer Ingelheim

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?